Jie Liu

Jie Liu

Managing Director

New York Office  |

Jie Liu, a Managing Director at Torreya, leads the company’s operations in China. He has over 20 years of experience in the pharmaceutical and healthcare industries, mostly focused on global licensing and M&A. In his current role, Jie is active in a variety of transactions in both branded and generic opportunities in the US and China.

Jie joined Torreya in 2016 from Heritage Pharma, a subsidiary of Emcure Pharmaceuticals, where he was Vice President, Business Development and Licensing. Previously, he was Senior Director, Global Business Development at Teva, and held business development positions with increasing responsibilities at J&J, Cephalon, and Auxilium.

Notable transactions on which Jie advised prior to joining Torreya include Teva’s $3.5 billion acquisition of Auspex; Teva’s acquisition of Labrys Biologics for up to $825 million, including $200 million upfront; Teva’s collaboration with Microchips in implantable medical device for $35 million in equity investment and technology access fee; Testim co-promote between Auxilium and GSK; Provigil co-promote between Cephalon and Takeda; Cephalon’s $350 million stem cell deal with Mesoblast for $130 million upfront and a $220 million equity stake; Cephalon’s acquisition of ChemGenex for $231 million; and Cephlaon’s acquisition of Salmedix for $160 million.

Jie received a B.A. from Tianjin University in China and an M.B.A. in healthcare from the Wharton School at the University of Pennsylvania. Jie is a native Mandarin speaker, and is licensed in the US as a speech pathologist.

Selected Transactions

Sesen Bio
License of Vicineum™ in Greater China Region to
Qilu Pharmaceutical
$12 million upfront
July 2020
License of Feraccru® in China to
Beijing Aosaikang Pharmaceutical
$62.8 million
January 2020
License of NOV03
in North America to
Bausch Health
December 2019
License of Gemcabene
in China to
SL Pharm
July 2019
License of Nefecon in Greater China and Singapore to
Up to $121 million
June 2019
License of Ravicti® in the Greater China Area, South Korea and Southeast Asia by
December 2020
License of Galinpepimut-S in Greater China by
3D Medicines
Up to $202 million with $7.5 million upfront
December 2020
Indivior PLC
Divestiture of China right of Sai Bo Song™ (buprenorphine, naloxone) tablet to
Zhejiang Pukang Biotechnology Co.
Up to $122.5 million
February 2019
JV Partnership
in China with
$50 million
December 2018
License of Durasert™ in Ophthalmology in the Greater China Region to
Ocumension Therapeutics
Up to $11.75 million
November 2018
EA Pharma
License of AJT-240 in hemodialysis in China to
Tasly Pharmaceutical Group Co., Ltd.
Up to $24 million
June 2018